Key terms
About PLRX
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PLRX news
Nov 19
1:56am ET
Positive Developments in Pliant Therapeutics’ IPF Research Bolster Buy Rating
Nov 18
10:55pm ET
Pliant Therapeutics Reports Increased Losses and Strategic Focus
Nov 11
6:55am ET
Promising Pipeline and Strong Financials Reinforce Buy Rating for Pliant Therapeutics
Nov 11
1:26am ET
Buy Rating on Pliant Therapeutics Driven by Promising Bexotegrast Developments and Strategic Market Positioning
Nov 08
9:36am ET
Positive Clinical Progress and Promising Data Support Buy Rating for Pliant Therapeutics
Nov 08
9:06am ET
Oppenheimer Sticks to Their Buy Rating for Pliant Therapeutics (PLRX)
Nov 08
7:09am ET
RBC Capital Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)
Nov 08
6:20am ET
3 Best Stocks to Buy Now, 11/8/2024, According to Top Analysts
Nov 08
5:17am ET
Positive Outlook on Pliant Therapeutics: Strategic Developments and Financial Stability Support Buy Rating
Nov 07
10:45pm ET
Pliant Therapeutics (PLRX) Receives a Buy from TD Cowen
Nov 07
4:56pm ET
Pliant Therapeutics reports Q3 EPS (95c), consensus (97c)
Oct 17
8:10am ET
Pliant Therapeutics highlights INTEGRIS-PSC Phase 2a data on bexotegrast
Sep 24
8:20am ET
Aligos Therapeutics appoints Hardean Achneck as CMO
Sep 17
6:57am ET
Pliant Therapeutics (PLRX) Gets a Buy from Piper Sandler
Sep 16
2:16am ET
Bullish on Bexo: Pliant Therapeutics’ Promising IPF Treatment Backed by Strong Clinical Evidence
Sep 13
6:26am ET
Buy Rating Affirmed for Pliant Therapeutics on Strong Bexotegrast Clinical Data and Broad Therapeutic Potential
Sep 10
8:20am ET
Pliant Therapeutics presents data from its Bexotegrast program
Sep 09
6:30am ET
Pliant Therapeutics assumed with an Outperform at Leerink
Sep 05
7:36am ET
Oppenheimer Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)
No recent press releases are available for PLRX
PLRX Financials
Key terms
Ad Feedback
PLRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PLRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
